Unlocking Epigenetics

CellCentric has a dominant discovery platform in epigenetics, based on an unparalleled worldwide hub & spoke network of over 30 leading researchers at major Institutions.

CellCentric’s unique, global platform has enabled the company to identify, prioritize and rapidly progress new therapeutic targets for drug discovery - ahead of its competitors.  CellCentric has seven epigenetic based drug discovery programs underway. 
 

CellCentric’s focus is to unlock the therapeutic potential of epigenetics by discovering new anti-cancer drugs acting on novel unexploited epigenetic targets.

CellCentric has also identified a broad range of research tools and cell reprogramming technologies for early commercialisation with selected partners.